NCT01134341 2019-12-18
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Phase 1 Completed
Acrotech Biopharma Inc.
European Organisation for Research and Treatment of Cancer - EORTC
Vanderbilt University
University College, London
National Cancer Institute (NCI)
Boston University